J
Julien Adam
Researcher at Université Paris-Saclay
Publications - 45
Citations - 1170
Julien Adam is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: ERCC1 & DNA repair. The author has an hindex of 13, co-authored 45 publications receiving 790 citations. Previous affiliations of Julien Adam include Institut Gustave Roussy & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.
Maud Toulmonde,Nicolas Penel,Julien Adam,Julien Adam,Christine Chevreau,Jean-Yves Blay,Axel Le Cesne,Emmanuelle Bompas,Sophie Piperno-Neumann,Sophie Cousin,Thomas Grellety,Thomas Ryckewaert,Alban Bessede,François Ghiringhelli,Marina Pulido,Antoine Italiano +15 more
TL;DR: It is found that PD-1 inhibition has limited activity in selected STS and GIST, and may be explained by an immunosuppressive tumor microenvironment resulting from macrophage infiltration and IDO1 pathway activation.
Journal ArticleDOI
Cisplatin resistance associated with PARP hyperactivation.
Judith Michels,Ilio Vitale,Lorenzo Galluzzi,Julien Adam,Ken A. Olaussen,Oliver Kepp,Laura Senovilla,Ibtissam Talhaoui,Justine Guegan,David Enot,Monique Talbot,Angélique Robin,Philippe Girard,Cedric Orear,Delphine Lissa,Abdul Qader Sukkurwala,Pauline Garcia,Parviz Behnam-Motlagh,Kimitoshi Kohno,Gen Sheng Wu,Catherine Brenner,Philippe Dessen,Murat Saparbaev,Jean-Charles Soria,Maria Castedo,Guido Kroemer +25 more
TL;DR: It is shown that PARP1 is highly expressed and constitutively hyperactivated in a majority of human CDDP-resistant cancer cells of distinct histologic origin, becoming susceptible to PARP inhibitor-induced apoptosis.
Journal ArticleDOI
Baseline metabolic tumor burden on FDG PET/CT scans predicts outcome in advanced NSCLC patients treated with immune checkpoint inhibitors.
Romain-David Seban,Laura Mezquita,Arnaud Berenbaum,Laurent Dercle,Angela Botticella,Cécile Le Péchoux,Caroline Caramella,Eric Deutsch,Serena Grimaldi,Julien Adam,Samy Ammari,David Planchard,Sophie Leboulleux,Benjamin Besse +13 more
TL;DR: Baseline tumor burden (TMTV) on FDG PET/CT scans and inflammatory status (dNLR) were associated with poor OS and absence of DCB for ICI treatment in advanced NSCLC patients, unlike tumor SUVmax, and may be used together to improve the selection of appropriate candidates.
Journal ArticleDOI
TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.
Charlotte Leduc,Charlotte Leduc,Julien Adam,Emilie Louvet,Emilie Louvet,Tony Sourisseau,Tony Sourisseau,Nicolas Dorvault,Nicolas Dorvault,Marine Bernard,Marine Bernard,Elodie Maingot,Elodie Maingot,Laura Faivre,Mei-Shiue Cassin-Kuo,Mei-Shiue Cassin-Kuo,Emilie Boissier,Emilie Boissier,Marie-Charlotte Dessoliers,Marie-Charlotte Dessoliers,Angélique Robin,Angélique Robin,Odile Casiraghi,Caroline Even,Stéphane Temam,Ken A. Olaussen,Ken A. Olaussen,Jean-Charles Soria,Sophie Postel-Vinay +28 more
TL;DR: TPF induction chemotherapy in advanced HNSCC increases PD-L1 positivity on tumour-infiltrating ICs, as well as CD8+ lymphocytes density, which warrant independent validation on larger datasets and might help therapeutic strategy in advancedHNSCC.
Journal ArticleDOI
CD103+CD8+ TRM Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17.
Stéphanie Corgnac,Ines Malenica,Laura Mezquita,Edouard Auclin,Elodie Voilin,Jamila Kacher,Heloise Halse,Laetitia Grynszpan,Nicolas Signolle,Thibault Dayris,Marine Leclerc,Nathalie Droin,Vincent Thomas de Montpréville,Olaf Mercier,Pierre Validire,Jean-Yves Scoazec,Christophe Massard,Salem Chouaib,David Planchard,Julien Adam,Benjamin Besse,Fathia Mami-Chouaib +21 more
TL;DR: Using quantitative multiplex immunofluorescence on cohorts of non-small cell lung cancer patients treated with anti-PD-(L)1, it is shown that an increased density of CD103+CD8+ lymphocytes in immunotherapy-naive tumors is associated with greatly improved outcomes.